NO971903L - Krystallisering av levobupivacain og analoger derav - Google Patents

Krystallisering av levobupivacain og analoger derav

Info

Publication number
NO971903L
NO971903L NO971903A NO971903A NO971903L NO 971903 L NO971903 L NO 971903L NO 971903 A NO971903 A NO 971903A NO 971903 A NO971903 A NO 971903A NO 971903 L NO971903 L NO 971903L
Authority
NO
Norway
Prior art keywords
pct
levobupivacaine
analogs
crystallization
sec
Prior art date
Application number
NO971903A
Other languages
English (en)
Other versions
NO309266B1 (no
NO971903D0 (no
Inventor
Marianne Langston
Benjamin Mark Skead
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421476A external-priority patent/GB9421476D0/en
Priority claimed from GBGB9504926.8A external-priority patent/GB9504926D0/en
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of NO971903D0 publication Critical patent/NO971903D0/no
Publication of NO971903L publication Critical patent/NO971903L/no
Publication of NO309266B1 publication Critical patent/NO309266B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
NO971903A 1994-10-25 1997-04-24 Fremgangsmåte for fremstilling av optisk anriket bupivacain NO309266B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9421476A GB9421476D0 (en) 1994-10-25 1994-10-25 Process and salt
GBGB9504926.8A GB9504926D0 (en) 1995-03-10 1995-03-10 Crystallisation
PCT/GB1995/002513 WO1996012699A1 (en) 1994-10-25 1995-10-23 Crystallisation of levobupivacaine and analogues thereof

Publications (3)

Publication Number Publication Date
NO971903D0 NO971903D0 (no) 1997-04-24
NO971903L true NO971903L (no) 1997-04-24
NO309266B1 NO309266B1 (no) 2001-01-08

Family

ID=26305863

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971903A NO309266B1 (no) 1994-10-25 1997-04-24 Fremgangsmåte for fremstilling av optisk anriket bupivacain

Country Status (16)

Country Link
US (1) US5994548A (no)
EP (1) EP0788480B1 (no)
JP (1) JP3911545B2 (no)
AT (1) ATE245629T1 (no)
AU (1) AU698637B2 (no)
CA (1) CA2200355C (no)
DE (1) DE69531356T2 (no)
DK (1) DK0788480T3 (no)
ES (1) ES2202375T3 (no)
FI (1) FI117438B (no)
HU (1) HU227420B1 (no)
MX (1) MX9703024A (no)
NO (1) NO309266B1 (no)
PL (1) PL183210B1 (no)
PT (1) PT788480E (no)
WO (1) WO1996012699A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0002246A (pt) * 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
BRPI0104491B8 (pt) * 2001-10-10 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP1575569B1 (en) 2002-12-13 2010-09-29 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US7094812B2 (en) * 2003-04-24 2006-08-22 Xerox Corporations Colorant compositions
US6790267B1 (en) * 2003-04-24 2004-09-14 Xerox Corporation Colorant compositions
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007123405A1 (en) * 2006-04-25 2007-11-01 Dishman Pharmaceuticals And Chemicals Ltd. Ropivacaine hydrochloride anhydrate and the preparation thereof
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
US8415401B2 (en) 2007-12-06 2013-04-09 Durect Corporation Oral pharmaceutical dosage forms
DK2234974T3 (da) * 2008-01-15 2012-06-25 Pharmathen Sa Fremgangsmåde til fremstilling af (S)-1-alkyl-2',6'-pipecoloxylidid-forbindelse
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN103073484B (zh) * 2013-01-28 2014-10-22 山东诚创医药技术开发有限公司 一种甲哌卡因及其光学对映体的制备方法
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
BR112019013192A2 (pt) * 2016-12-26 2019-12-10 Cellix Bio Private Ltd composto e composição farmacêutica
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE341404B (no) * 1967-05-18 1971-12-27 Sterling Drug Inc
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide

Also Published As

Publication number Publication date
PL183210B1 (pl) 2002-06-28
JPH10507464A (ja) 1998-07-21
CA2200355C (en) 2007-03-06
AU698637B2 (en) 1998-11-05
NO309266B1 (no) 2001-01-08
EP0788480B1 (en) 2003-07-23
FI117438B (fi) 2006-10-13
WO1996012699A1 (en) 1996-05-02
PL319829A1 (en) 1997-09-01
FI971711A (fi) 1997-04-22
US5994548A (en) 1999-11-30
NO971903D0 (no) 1997-04-24
DE69531356T2 (de) 2004-05-27
MX9703024A (es) 1997-10-31
EP0788480A1 (en) 1997-08-13
ATE245629T1 (de) 2003-08-15
PT788480E (pt) 2003-12-31
HUT77631A (hu) 1998-06-29
DK0788480T3 (da) 2003-09-29
CA2200355A1 (en) 1996-05-02
FI971711A0 (fi) 1997-04-22
HU227420B1 (en) 2011-05-30
JP3911545B2 (ja) 2007-05-09
ES2202375T3 (es) 2004-04-01
DE69531356D1 (de) 2003-08-28
AU3704895A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
NO971903L (no) Krystallisering av levobupivacain og analoger derav
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
DE69200983T2 (de) Verfahren zur Herstellung von Wasserstoffsuperoxyd.
DE69307509T2 (de) Vorrichtung zur behandlung von herzfehlern
NO308397B1 (no) Desinfiseringsmiddelblanding, fremgangsmÕte for fremstilling derav og anvendelse av denne, samt to-pakkesystem
DK0581959T3 (da) Anvendelse af makrolidforbindelser til øjensygdomme
ATE153022T1 (de) 3',5'-ditertbutyl-4'-hydroxyflavone, verfahren zu ihrer herstellung und pharmazeutische zusammensetzung mit antioxidations- und antivasokonstriktionsaktivität
ATE86978T1 (de) Verfahren zur herstellung von 3,5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer.
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
ATE81976T1 (de) 2-pyrimidinyl-1-piperazin-derivate zur behandlung von alkoholismus.
DE69202680D1 (de) Verfahren zur Herstellung von Wasserstoffperoxyd.
PT83309A (de) Neue pyrrolo-benzimidazole pyrrolo-benzoxazole und pyrrolo-benzthiazole verfahren zu ihrer herstellung und diese verbindungen enthaltende arneimittel
DK0476113T3 (da) Lægemiddel til behandling af hyperlipidæmi og/eller atherosklerose
DK0821588T3 (da) Levobupivacain og anvendelse heraf som et anæstetikum til gravide kvinder
DE59105224D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolidonen.
ATE69795T1 (de) Verfahren zur herstellung von ethylenischen carbonylverbindungen.
DE59407675D1 (de) Verfahren zur Herstellung von 6H-Dibenz-(c,e)(1,2)-oxaphosphorin-6-on
ATE157660T1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
DE69210069T2 (de) Verfahren zur Herstellung von 1,3-Dioxolen
ES2162078T3 (es) Compuestos terapeuticos.
DE69210933T2 (de) Verfahren zur Herstellung von Alpha, Omega-Dihydroxyperfluoroalkylethylmethylpolysiloxanen
DE69103913D1 (de) Verfahren zur Herstellung von Dodekandicarbonsäure.
ATE84780T1 (de) Neue di(meth)acrylate, verfahren zu deren herstellung und deren verwendung.
ATE128188T1 (de) Menschliches gamma-interferon, verfahren zu seiner herstellung und seine verwendung.
DE3764330D1 (de) 2,2;6,6-diethylen-3-oxo-17alpha-pregn-4-en-21, 17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharm. praeparate.

Legal Events

Date Code Title Description
MK1K Patent expired